DSpace Collection:https://hdl.handle.net/10171/520602024-03-29T09:44:23Z2024-03-29T09:44:23ZConsensus guidelines for the definition, detection and interpretation of immunogenic cell deathhttps://hdl.handle.net/10171/667502024-01-24T09:29:39Z2020-01-01T00:00:00ZTitle: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Abstract: Cells succumbing to stress via regulated cell death (RCD)
can initiate an adaptive immune response associated
with immunological memory, provided they display
sufficient antigenicity and adjuvanticity. Moreover, multiple
intracellular and microenvironmental features determine
the propensity of RCD to drive adaptive immunity. Here, we
provide an updated operational definition of immunogenic
cell death (ICD), discuss the key factors that dictate
the ability of dying cells to drive an adaptive immune
response, summarize experimental assays that are
currently available for the assessment of ICD in vitro and in
vivo, and formulate guidelines for their interpretation.2020-01-01T00:00:00ZFirst-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumorshttps://hdl.handle.net/10171/662262023-05-22T05:12:28Z2020-01-01T00:00:00ZTitle: First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors
Abstract: Agonistic 4-1BB monoclonal antibodies were preclinically validated as promising cancer immunotherapies, both
as monotherapy and as potentiators of the activity of PD-(L)
1–blocking agents. However, toxicity and a narrow therapeutic
window have hampered their clinical development. DuoBodyPD-L1×4-1BB, a first-in-class, bispecific, next-generation
checkpoint immunotherapy, was designed to overcome these
limitations by activating T cells through conditional 4-1BB costimulation, while simultaneously blocking the PD-L1 axis. We
present preliminary data from the ongoing, first-in-human,
open-label, phase I/IIa trial of DuoBody-PD-L1×4-1BB in
advanced solid tumors (NCT03917381).2020-01-01T00:00:00ZStarting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)https://hdl.handle.net/10171/656122024-02-09T11:56:43Z2018-01-01T00:00:00ZTitle: Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Abstract: A European Society for Medical Oncology (ESMO)-sponsored expert meeting was held in Paris on 8 March 2018 which comprised 11 experts from academia, 11 experts from the pharmaceutical industry and 2 clinicians who were representatives of ESMO. The focus of the meeting was exclusively on the intratumoral injection/delivery of immunostimulatory agents with the aim of harmonizing the standard terms and methodologies used in the reporting of human intratumoral immunotherapy (HIT-IT) clinical trials to ensure quality assurance and avoid a blurring of the data reported from different studies. The goal was
to provide a reference document, endorsed by the panel members that could provide guidance to clinical investigators, pharmaceutical companies, ethics committees, independent review boards, patient advocates and the regulatory authorities
and promote an increase in the number and quality of HIT-IT clinical trials in the future. Particular emphasis was placed not only on the development of precise definitions to facilitate a better understanding between investigators but also on the
importance of systematic serial biopsies as a driver for translational research and the need for the recording and reporting of data, to facilitate a better understanding of the key processes involved.2018-01-01T00:00:00ZGeneration of four Isl1 reporter iPSC lines from cardiac and tail-tip fibroblasts derived from Ai6IslCre mousehttps://hdl.handle.net/10171/648522024-01-24T09:36:38Z2018-01-01T00:00:00ZTitle: Generation of four Isl1 reporter iPSC lines from cardiac and tail-tip fibroblasts derived from Ai6IslCre mouse
Abstract: Islet-1 (Isl1) is a transcription factor essential for life expressed in specific cells with different developmental origins. We have generated iPSC lines from fibroblasts of
the transgenic Ai6 x Isl1-Cre (Ai6IslCre) mouse. Here we describe the complete characterization of four iPSC lines: ATCi-Ai6IslCre10, ATCi-Ai6IslCre35, ATCiAi6IslCre74 and ATCi-Ai6IslCre80.2018-01-01T00:00:00Z